MAPT and Alzheimer disease: TRAILBLAZER-ALZ 2 (n = 1800, 2020–2025, NCT04437511) tested donanemab in a 76-week, randomized, placebo-controlled, double-blind, phase 3 study in MCI or mild dementia due to AD, confirmed by brain Aβ PET and by brain tau PET showing intermediate or high tau levels [92].